Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

M&T Bank Corp lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 23.4% in the fourth ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.

Let’s discuss how Tardive Dyskinesia (TD) affects your life and what you can do to overcome these difficulties.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of investigational ...

Neurocrine Biosciences (Nasdaq: NBIX) has announced positive results from its Phase IV KINECT-PRO study, showing that Ingrezza (valbenazine) provided meaningful and sustained benefits for patients ...

Biosciences announced top-line data from a Phase 4 study, KINECT-PRO, demonstrating clinically meaningful and sustained ...

Tardive dyskinesia places high physical, social, and psychological burdens on patients and their caregivers. A new online survey of U.S. caregivers spotlights their struggles. Share on Facebook.

Neurocrine Biosciences, Inc. will participate at two upcoming investor conferences in March. Chief Executive Officer Kyle ...

Tardive dyskinesia (TD) is an involuntary movement condition, meaning you can't control your movements. "Tardive" means late, and "dyskinesia" means uncontrolled movements. It's often a side ...